FAM167A

FAM167A (DIORA-1) is a highly intrinsically disordered protein, conserved across species and belonging to a small gene family (FAM167A/FAM167B) with no homology to other annotated genes, that is most highly expressed in lung bronchial epithelium and alveolar macrophages where it shows an endosomal localization pattern (PMID:29663334). Functionally, FAM167A activates the noncanonical NF-κB pathway: it binds the cell adhesion protein desmoglein-1 (DSG1) and blocks ubiquitination of NF-κB-inducing kinase (NIK), stabilizing NIK and driving BCR-ABL-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia (PMID:35241148). Its expression is governed by the FAM167A-BLK risk locus, where risk genotypes are associated with elevated FAM167A mRNA and reduced BLK expression in B cells (PMID:18204098), and BLK itself regulates FAM167A expression levels (PMID:41250293). Beyond these findings, the structural basis of FAM167A's interactions and its physiological role in its endosomal context remain uncharacterized in the available corpus.

1. 2008 Medium

   Establishing why FAM167A first drew attention required linking it to disease genetics, and an autoimmune-associated risk allele at the FAM167A-BLK locus was found to track with FAM167A expression, implicating the gene as a candidate effector of locus genotype.

   Evidence eQTL analysis in B-cell lines correlating rs13277113 genotype with mRNA levels

   PMID:18204098

   Open questions at the time

   • Correlation does not establish which gene at the locus drives the disease phenotype
   • No functional perturbation to test causality
   • Does not address FAM167A protein function
2. 2018 Medium

   With no known homologs, the basic biochemical and cellular identity of FAM167A was unknown; cloning and tissue mapping defined it as a highly disordered protein with lung-predominant expression and endosomal localization.

   Evidence Cloning from human PBMCs, IHC of human tissues, protein disorder prediction, qPCR in mouse organs

   PMID:29663334

   Open questions at the time

   • No molecular function or binding partner identified
   • Disorder predicted bioinformatically, not validated structurally
   • Endosomal role not functionally tested
3. 2022 High

   The molecular activity of FAM167A was undefined until it was shown to act as a noncanonical NF-κB activator, binding DSG1 to stabilize NIK and confer kinase-inhibitor resistance, giving the protein a concrete signaling mechanism.

   Evidence MS-based receptor identification, Co-IP, NIK ubiquitination assays, in vivo mouse tumor models and CML patient cell validation

   PMID:35241148

   Open questions at the time

   • Structural basis of the FAM167A-DSG1 interaction not defined
   • Mechanism by which DSG1 binding blocks NIK ubiquitination unresolved
   • Connection to the endosomal localization reported earlier not addressed
4. 2025 Medium

   Whether the FAM167A-BLK risk locus acts directly on FAM167A or through BLK was unresolved; fine-mapping showed the functional SNPs drive BLK rather than FAM167A, and that BLK in turn regulates FAM167A expression.

   Evidence Dual-luciferase reporters, shRNA and CRISPR/dCas9 knockdown, functional GWAS annotation

   PMID:41250293

   Open questions at the time

   • Mechanism of BLK-mediated regulation of FAM167A not defined
   • Apparent tension with earlier eQTL linking risk allele directly to FAM167A mRNA
   • Single study, no independent replication

• How FAM167A's intrinsic disorder, endosomal localization, and DSG1/NIK signaling activity integrate into a single physiological function remains unresolved.
• No structural model of FAM167A or its complexes
• Physiological role in lung epithelium/macrophages versus its leukemia signaling role not reconciled
• Function of FAM167B and the family more broadly uncharacterized